首页 | 本学科首页   官方微博 | 高级检索  
     


Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): A report from the Children's Oncology Group
Authors:Todd M. Cooper DO  Bassem I. Razzouk MD  Robert Gerbing MA  Todd A. Alonzo PhD  Kathleen Adlard RN  Elizabeth Raetz MD  Alan S. Gamis MD  John Perentesis MD  James A. Whitlock MD
Affiliation:1. Aflac Cancer and Blood Disorders Center/Children's Healthcare of Atlanta/Emory University, Atlanta, Georgia;2. Children's Center for Cancer and Blood Diseases, Peyton Manning Children's Hospital at St Vincent, Indianapolis, Indiana;3. Children's Oncology Group, Arcadia, California;4. Keck School of Medicine University of Southern California, Los Angeles, California;5. Children's Hospital of Orange County, Orange, California;6. Division of Hematology–Oncology, Department of Pediatrics, New York University School of Medicine and Cancer Institute, New York, New York;7. Children's Mercy Hospital and Clinics, Kansas City, Missouri;8. Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio;9. Garron Family Cancer Center, Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada
Abstract:
Keywords:acute lymphoblastic leukemia  clofarabine  cytarabine  pediatric
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号